Sorry, you need to enable JavaScript to visit this website.

VIZIMPRO® Tablets (dacomitinib) Indications and Usage

1 INDICATIONS AND USAGE

VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1)].

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No